AMPD2

AMPD2, or adenosine monophosphate deaminase 2, is an enzyme crucial for cellular energy management, encoded by the AMPD2 gene located on chromosome 1p21-p34. 

This enzyme facilitates the conversion of adenosine monophosphate (AMP) to inosine monophosphate (IMP) within the purine nucleotide cycle, a process vital for regulating cellular energy levels, particularly in the liver, brain, and kidneys. 

Beyond its biochemical role, mutations in the AMPD2 gene are linked to several serious conditions including pontocerebellar hypoplasia and spastic paraplegia, underscoring its significance in both metabolic and neurological health. 

The gene's variants, AMPD1 and AMPD3, cater to specific functions in skeletal muscles and red blood cells, respectively, highlighting a complex genetic system that maintains energy balance and supports various organ systems under metabolic stress.

What is AMPD2?  [2., 3., 4., 6., 7., 8.]

AMPD2, or Adenosine Monophosphate Deaminase 2, is a gene that codes for the enzyme AMPD2.  The AMPD2 enzyme plays a pivotal role in the metabolic processes essential for energy conservation and utilization in cells. 

The AMPD2 gene is located on chromosome 1p21-p34.  

AMPD2 is responsible for the deamination of adenosine monophosphate (AMP) to inosine monophosphate (IMP), a crucial step in the purine nucleotide cycle that helps regulate energy balance within the cell.  

The AMPD2 gene has variants, AMPD1 and AMPD3, which are responsible for the skeletal muscle- and erythrocyte-specific isoforms, respectively. 

The AMPD2 enzyme is considered the liver isoform of the AMPD2 enzyme, and is expressed in the liver, brain and kidneys.

By controlling the levels of AMP and IMP, AMPD2 directly influences the synthesis and degradation of ATP (adenosine triphosphate), the cell's primary energy currency. This role is vital for maintaining cellular energy homeostasis, especially during periods of high energy demand or metabolic stress.

Mutations in the AMPD2 gene have been associated with several disorders, such as pontocerebellar hypoplasia type 9 and spastic paraplegia 63.  

A specific mutation in the AMPD2 gene, resulting in an alanine to serine conversion at amino acid 341, has been linked to nephrotic syndrome and hypercholesterolemia in mice.  This mutation leads to a complete loss of AMPD2 protein expression in homozygous mutant mice, suggesting the importance of AMPD2 in maintaining normal kidney and lipid metabolism.  [HELMERING

AMPD2 and Its Role in Disease

AMPD2 dysfunction is associated with a variety of metabolic and neurological disorders, highlighting its critical role in maintaining cellular and systemic health. 

Pontocerebellar Hypoplasia Type 9 (PCH9)  [4., 6., 8.]

Pontocerebellar hypoplasia type 9 (PCH9) is a severe neurodegenerative disorder caused by mutations in the AMPD2 gene.  Patients exhibit pontocerebellar hypoplasia, dysmorphisms, and teeth abnormalities.  

A homozygous truncating mutation (Y752X) in AMPD2 was found in 4 affected siblings, leading to complete absence of the AMPD2 protein.

Spastic Paraplegia 63 (SPG63)  [4., 6.]

Spastic paraplegia 63 (SPG63) is an autosomal recessive form of hereditary spastic paraplegia associated with AMPD2.  In a consanguineous family, a homozygous 1-bp deletion (318delT) in AMPD2 was identified in affected individuals, resulting in a frameshift and premature termination.

Nephrotic Syndrome and Hypercholesterolemia  [8.]

Nephrotic syndrome and hypercholesterolemia were observed in mice with a specific mutation in the Ampd2 gene, resulting in an alanine to serine conversion at amino acid 341.  This mutation led to complete loss of Ampd2 protein expression in homozygous mutant mice.  The combined phenotypes of nephrotic syndrome and hypercholesterolemia have not been previously reported in Ampd2 knockout mice.

Neurodegenerative Brainstem Disorder  [4.]

A potentially treatable neurodegenerative brainstem disorder was associated with possession of the AMPD2 T allele, which was linked to decreased inotropic requirements before heart donation.  

Further research is needed to elucidate the exact mechanisms by which AMPD2 mutations contribute to this condition.

Genetic Alterations in the AMPD2 Gene

The gene for the AMPD2 protein may contain alterations or mutations that cause increase or decrease of function of the AMPD2 protein.  

Testing for genetic alterations in the form of SNPs is increasingly available and can shed light on an individual’s potential for health and disease.  

What is a SNP?

A SNP, or single nucleotide polymorphism, refers to a variation at a single position in a gene along its DNA sequence.  A gene encodes a protein, so an alteration in that gene programs the production of an altered protein.  

As a type of protein with great functionality in human health, alterations in genes for enzymes may confer a difference in function of that enzyme.  The function of that enzyme may be increased or decreased, depending on the altered protein produced.  

SNPs are the most common type of genetic variation in humans and can occur throughout the genome, influencing traits, susceptibility to diseases, and response to medications.

The completion of the Human Genome Project has significantly expanded opportunities for genetic testing by providing a comprehensive map of the human genome that facilitates the identification of genetic variations associated with various health conditions, including identifying SNPs that may cause alterations in protein structure and function.  

Genetic testing for SNPs enables the identification of alterations in genes, shedding light on their implications in health and disease susceptibility.

Specific SNPs Associated with Altered Function of AMPD2  [1.]

Y752X

A homozygous truncating mutation (Y752X) in AMPD2 was found in 4 affected siblings with pontocerebellar hypoplasia type 9 (PCH9), leading to complete absence of the AMPD2 protein.

318delT

A homozygous 1-bp deletion (318delT) in AMPD2 was identified in affected individuals with spastic paraplegia 63 (SPG63) in a consanguineous family, resulting in a frameshift and premature termination.  

These mutations in the AMPD2 gene lead to either complete absence of the protein or altered protein structure and stability, resulting in various neurological and metabolic disorders.

Laboratory Testing for AMPD2

Genetic testing for single nucleotide polymorphisms (SNPs) typically involves obtaining a sample of DNA which can be extracted from blood, saliva, or cheek swabs. 

The sample may be taken in a lab, in the case of a blood sample.  Alternatively, a saliva or cheek swab sample may be taken from the comfort of home. 

Test Preparation

Prior to undergoing genetic testing, it's important to consult with a healthcare provider or genetic counselor to understand the purpose, potential outcomes, and implications of the test.  This consultation may involve discussing medical history, family history, and any specific concerns or questions. 

Additionally, individuals may be advised to refrain from eating, drinking, or chewing gum for a short period before providing a sample to ensure the accuracy of the test results.  Following sample collection, the DNA is processed in a laboratory where it undergoes analysis to identify specific genetic variations or SNPs. 

Once the testing is complete, individuals will typically receive their results along with interpretation and recommendations from a healthcare professional. 

It's crucial to approach genetic testing with proper understanding and consideration of its implications for one's health and well-being.

Patient-Centric Approaches

A patient-centered approach to SNP genetic testing emphasizes individualized medicine, tailoring healthcare decisions and interventions based on an individual's unique genetic makeup.

When that is combined with the individual’s health status and health history, preferences, and values, a truly individualized plan for care is possible. 

By integrating SNP testing into clinical practice, healthcare providers can offer personalized risk assessment, disease prevention strategies, and treatment plans that optimize patient outcomes and well-being. 

Genetic testing empowers a deeper understanding of genetic factors contributing to disease susceptibility, drug response variability, and overall health, empowering patients to actively participate in their care decisions. 

Furthermore, individualized medicine recognizes the importance of considering socioeconomic, cultural, and environmental factors alongside genetic information to deliver holistic and culturally sensitive care that aligns with patients' goals and preferences. 

Through collaborative decision-making and shared decision-making processes, patients and providers can make informed choices about SNP testing, treatment options, and lifestyle modifications, promoting patient autonomy, engagement, and satisfaction in their healthcare journey.

Genetic Panels and Combinations

Integrating multiple biomarkers into panels or combinations enhances the predictive power and clinical utility of pharmacogenomic testing.  

Biomarker panels comprising a variety of transporter proteins and enzymes including drug metabolizing enzymes offer comprehensive insights into individual drug response variability and treatment outcomes. 

Combining genetic SNP testing associated with drug transport, metabolism, and pharmacodynamics enables personalized medicine approaches tailored to individual patient characteristics and genetic profiles.

AMPD2-Related Biomarkers in Metabolic Assessment

In the study and management of disorders involving AMPD2, other biomarkers provide additional insights into the metabolic pathways affected by AMPD2 dysfunction and can help in diagnosing, monitoring, and treating related conditions. 

AMPD1

AMPD1, like AMPD2, is involved in the purine nucleotide cycle where it plays a similar role in the deamination of adenosine monophosphate (AMP) to inosine monophosphate (IMP).  The activities of both AMPD1 and AMPD2 are crucial for maintaining cellular energy balance, especially in muscle tissues. 

While AMPD1 is primarily expressed in skeletal muscle, AMPD2 is more widely distributed, including in the nervous system.  Understanding the relationship between these two enzymes can help clarify the symptoms and management of diseases where energy metabolism is disrupted, such as myopathies and neurological disorders.

ADSL (Adenylosuccinate Lyase)  [10., 11., 12.]

Adenylosuccinate lyase (ADSL) is another important enzyme in purine metabolism, working in concert with AMPD1.  ADSL is responsible for converting adenylosuccinate to AMP and fumarate in the purine nucleotide cycle, a pathway shared with AMPD1. 

Disruptions in ADSL can lead to adenylosuccinase deficiency, which can present symptoms similar to those of myoadenylate deaminase deficiency, such as muscle fatigue and neurological issues. 

By evaluating ADSL activity alongside AMPD1, clinicians can better understand the extent of metabolic disruption and differentiate between these related conditions.

PKM (Pyruvate Kinase, Muscle)  [15.] 

Pyruvate kinase, muscle isoform (PKM), is crucial for glycolysis, the process that breaks down glucose to produce energy.  Changes in PKM activity can indicate broader metabolic issues that might also affect AMPD1 pathways. 

Since both AMPD1 and PKM are involved in energy production within muscle cells, abnormalities in PKM can complement data from AMPD1 testing, offering a more comprehensive view of a patient's metabolic state.  This is particularly useful in cases where muscle energy metabolism is suspected to be impaired.

LDH (Lactate Dehydrogenase)  [5., 14.]

Lactate dehydrogenase (LDH) is an enzyme involved in converting pyruvate to lactate when oxygen levels are low, a process known as anaerobic metabolism. Elevated levels of LDH can be indicative of tissue damage or disease states where cells are under metabolic stress due to hypoxia or other factors. Since AMPD1 dysfunction can affect muscle endurance and recovery, LDH levels can provide indirect clues about the severity and impact of AMPD1-related conditions on muscle health.

Order Genetic Testing

Click here to compare genetic test panels and order genetic testing for health-related SNPs.